An Open Label, Phase I Study of BI 765063 Monotherapy, and Its Combination Therapy With BI 754091, to Characterize Safety, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Advanced Solid Tumors
Latest Information Update: 19 May 2022
At a glance
- Drugs BI 765063 (Primary) ; Ezabenlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 09 May 2022 Status changed from active, no longer recruiting to completed.
- 19 Apr 2022 Planned End Date changed from 11 Nov 2022 to 20 Apr 2022.
- 19 Apr 2022 Planned primary completion date changed from 6 May 2022 to 20 Apr 2022.